William Blair downgrades Neogenomics stock rating to Market Perform

Published 29/07/2025, 18:48
William Blair downgrades Neogenomics stock rating to Market Perform

Investing.com - William Blair downgraded Neogenomics (NASDAQ:NEO) from Outperform to Market Perform on Tuesday, citing concerns about the time needed to rebuild investor credibility. According to InvestingPro data, the company has seen its stock decline by over 60% year-to-date, despite maintaining solid revenue growth of 10.1%.

The downgrade comes as Neogenomics shares fell 20% in Tuesday morning trading to $5.10, reflecting what the research firm described as a "full washout" in the stock. This places the shares near their 52-week low, though InvestingPro analysis suggests the stock is currently undervalued.

William Blair noted that despite being encouraged by the company’s new messaging and commitment to rebuilding investor trust, these efforts typically require more than one quarter of execution to establish a compelling investment thesis beyond valuation alone.

The firm pointed out that Neogenomics currently trades at what it called a "dismal valuation" of 1 times next twelve months (NTM) sales and 14 times NTM EBITDA, both well below historical and peer group averages. The company maintains strong liquidity with a current ratio of 2.05, indicating sufficient assets to cover short-term obligations.

William Blair maintained its long-term positive outlook on the business, suggesting Neogenomics "could be a monster of a stock in 2026" if the company successfully executes its plans and rebuilds trust, potentially driving multiple expansion. Get deeper insights into NEO’s financial health metrics and growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, NeoGenomics announced its second-quarter 2025 earnings, reporting an earnings per share (EPS) of $0.03. This figure surpassed analysts’ expectations of $0.02, marking a 50% increase over the forecast. However, the company’s revenue fell short of projections, coming in at $181 million compared to the anticipated $183 million. Despite the EPS beat, the revenue miss was a focal point for investors. These developments have captured the attention of analysts and investors alike. The earnings results are part of the recent developments surrounding NeoGenomics. Market reactions to these results have been mixed, with the revenue shortfall being a significant factor. The company’s financial performance continues to be closely monitored by those in the investment community.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.